SHENZHEN, China, April 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will report its financial results for the first quarter ended March 31, 2009 after the U.S. market closes on May 11, 2009. Mindray's management will hold an earnings conference call at 8:00 AM on May 12, 2009 U.S. Eastern Time (8:00 PM on May 12, 2009 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows: Hong Kong: +852-3002-1672 U.S. Toll Free: +1-800-798-2864 International: +1-617-614-6206 Passcode for all regions: Mindray
A replay of the conference call may be accessed by phone at the following numbers until May 23, 2009.
U.S. Toll Free: +1-888-286-8010 International: +1-617-801-6888 Passcode: 9482 5654
Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://www.mindray.com .
Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has another 12 international sales and service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .
For investor and media inquiries please contact: In the U.S.: Evan Smith, CFA FD Tel: +1-212-850-5606 Email: firstname.lastname@example.org John Capodanno FD Tel: +1-212-850-5705 Email: email@example.com In China: Cathy Gao Mindray Medical International Limited Tel: +86-755-2658-2518 Email: firstname.lastname@example.org
|SOURCE Mindray Medical International Limited|
Copyright©2009 PR Newswire.
All rights reserved